The following is from The Vaccine Reaction. On Feb. 29, 2024, the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) presented a preliminary analysis that showed that 23 adults over the age of 65 […]
CDC Preliminary Analysis: RSV vaccines for seniors linked to Guillain-Barré Syndrome Read More »
The following is an excerpt from Medpage Today. The FDA has approved the first-ever vaccine for respiratory syncytial virus (RSV) the agency announced on Wednesday. Marketed under the trade name of Arexvy, the adjuvanted RSV prefusion F protein-based vaccine is specifically
FDA green lights first-ever RSV vaccine for adults 60+ Read More »
The following is an excerpt from MedPage Today. In two somewhat close votes, an FDA panel of outside experts recommended the agency approve Pfizer’s respiratory syncytial virus (RSV) vaccine for older adults, despite concerns over the potential risk for Guillain
FDA green lights new Pfizer RSV vaccine amid safety concerns Read More »
The following is a news analysis. An early adopter of Covid vaccines was a globally well-respected cardiologist named Dr. Aseem Malhotra. But when he says his own father died from the vaccine, he started investigating the science and studies. What
Note: Guillain Barre Syndrome (GBS) (autoimmune paralysis) is a recognized side effect from some vaccines, including Johnson and Johnson’s Covid-19 vaccine, according to recent warnings issued by FDA. There have been reports of GBS after other Covid-19 vaccines, but FDA
